Thierry Lesimple

9.2k total citations · 1 hit paper
139 papers, 3.3k citations indexed

About

Thierry Lesimple is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thierry Lesimple has authored 139 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 54 papers in Molecular Biology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thierry Lesimple's work include Melanoma and MAPK Pathways (27 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immunotherapy and Immune Responses (20 papers). Thierry Lesimple is often cited by papers focused on Melanoma and MAPK Pathways (27 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immunotherapy and Immune Responses (20 papers). Thierry Lesimple collaborates with scholars based in France, United States and Germany. Thierry Lesimple's co-authors include L. Thomas, Yacine Merrouche, Karim Fizazi, Stéphane Culine, Célèste Lebbé, Caroline Robert, Alain Lortholary, Laurent Mortier, Sylvie Négrier and Jean‐Jacques Grob and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Thierry Lesimple

130 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Philippe Saïag, Caroline Robert et al. profile →

Peers

Countries citing papers authored by Thierry Lesimple

Since Specialization

Citations

This map shows the geographic impact of Thierry Lesimple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Lesimple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Lesimple more than expected).

Fields of papers citing papers by Thierry Lesimple

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Lesimple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Lesimple. The network helps show where Thierry Lesimple may publish in the future.

Co-authorship network of co-authors of Thierry Lesimple

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Lesimple. A scholar is included among the top collaborators of Thierry Lesimple based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Lesimple. Thierry Lesimple is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study 2025 ·Annales de Dermatologie et de Vénéréologie ·Mara De Amici, Érik Neveu, F. Poizeau, Julien Edeline, Thierry Lesimple, Emmanuel Oger, (unknown), A. Dupuy, (unknown)	0
2	Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. 2024 ·Journal of Clinical Oncology ·Axel Hauschild, Reinhard Dummer, Mario Santinami, Victoria Atkinson, Mario Mandalà, Barbara Merelli, Vanna Chiarion‐Sileni, Andrew Haydon, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Elizabeth Ruth Plummer, James Larkin, Monique Tan, (unknown), Paul Burgess, (unknown), Georgina V. Long	2
3	The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma 2023 ·British Journal of Dermatology ·F. Poizeau, Frédéric Balusson, F. Lemaı̂tre, Camille Tron, Marc Pracht, David Russo, Monica Dinulescu, Thierry Lesimple, Emmanuel Oger, A. Dupuy	2
4	Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 2022 ·Clinical Cancer Research ·Caroline Robert, Célèste Lebbé, Thierry Lesimple, (unknown), (unknown), (unknown), (unknown), Barouyr Baroudjian, Émilie Routier, Ferdy J. Lejeune	15
5	734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Hans Prenen, Thierry Lesimple, Marie E. Robert, (unknown), Jean‐Pascal Machiels, Tarek Meniawy, Eric Van Cutsem, Nuria Kotecki, Sarina A. Piha‐Paul, Michael T. Schweizer, Shirish M. Gadgeel, (unknown), Louis Viviers, (unknown), Antoîne Italiano	2
6	Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial 2022 ·Cancers ·(unknown), (unknown), (unknown), G. Quéreux, A. Dupuy, Thierry Lesimple, Yannick Le Corre, E. Wierzbicka-Hainaut, Délphine Legoupil, P. Celérier, H. Maillard, L. Machet, Agnès Caille	2
7	The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy 2022 ·JNCI Journal of the National Cancer Institute ·F. Poizeau, Sandrine Kerbrat, Frédéric Balusson, Pierre Tattevin, Matthieu Revest, Vincent Cattoir, David Luque-Paz, Thierry Lesimple, Marc Pracht, Monica Dinulescu, David Russo, Emmanuel Oger, A. Dupuy	13
8	Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort 2022 ·JCO Precision Oncology ·(unknown), Stéphane Dalle, Laurent Mortier, S. Dalac, M.‐T. Leccia, Caroline Dutriaux, Henri Montaudié, Julie De Quatrebarbes, Thierry Lesimple, F. Brunet‐Possenti, Philippe Saïag, E. Maubec, Délphine Legoupil, Pierre‐Emmanuel Stoebner, J.-P. Arnault, (unknown), Célèste Lebbé, O. Dereure	6
9	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover 2020 ·Cancers ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, (unknown), Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	32
10	Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017 2020 ·Journal of Investigative Dermatology ·F. Poizeau, Sandrine Kerbrat, André Happe, (unknown), Erwan Drézen, Frédéric Balusson, Philippe Tuppin, B. Guillot, (unknown), (unknown), Monica Dinulescu, Marc Pracht, Thierry Lesimple, C. Droitcourt, Emmanuel Oger, A. Dupuy	8
11	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors 2020 ·Targeted Oncology ·Jean‐Pierre Delord, Antoîne Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Célèste Lebbé, (unknown), Thierry Lesimple, Monica Dinulescu, Jan H.M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Krüse, Richard Kefford, Sandrine Faivre, Carlos Gomez‐Roca, (unknown), (unknown), Éric Raymond	8
12	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial 2020 ·Targeted Oncology ·Célèste Lebbé, Antoîne Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H.M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Krüse, Richard Kefford, Éric Raymond, Sandrine Faivre, (unknown), Carlos Gomez‐Roca, Armin Schueler, (unknown), Giorgio Massimini, (unknown)	10
13	1133P Skin photoaging around the site of occurrence of primary melanoma as a clinical predictive biomarker of response to PD-1 inhibitors 2020 ·Annals of Oncology ·Domenico Russo, F. Poizeau, (unknown), R. Baggio, (unknown), (unknown), (unknown), Colombe Saillard, Marc Pracht, Thierry Lesimple, A. Dupuy, (unknown)	1
14	CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma 2016 ·Annals of Oncology ·Thierry Lesimple, Boris Campillo‐Gimenez, M.‐T. Leccia, (unknown), Célèste Lebbé	2
15	Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Iñaki F. Trocóniz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Patrick Delavault, F. Cvitkovic, Thierry Lesimple, R. Obach	18
16	A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas 2011 ·Clinical Cancer Research ·Marie de Tayrac, Marc Aubry, Stéphan Saïkali, Amandine Etcheverry, (unknown), Frédérique Guénot, Marie‐Dominique Galibert, Abderrahmane Hamlat, Thierry Lesimple, Véronique Quillien, Philippe Meneï, Jean Mosser	62
17	European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme 2003 ·Annals of Oncology ·Martin J. van den Bent, Wolfgang Grisold, Didier Frappaz, Roger Stupp, Julie Désir, Thierry Lesimple, C. Dittrich, Maja J.A. de Jonge, Alba A. Brandes, Marc Frénay, Alain Carpentier, P. Chollet, (unknown), B. Barón, Denis Lacombe, (unknown), P. Fumoleau	32
18	[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. 2002 ·PubMed ·R. Bugat, A Bataillard, Thierry Lesimple, Jean‐Jacques Voigt, Stéphane Culine, Alain Lortholary, Yacine Merrouche, G. Ganem, Marie‐Christine Kaminsky, Sylvie Négrier, M. Pérol, (unknown), Pierre Bédossa, G. Bertrand, Jean‐Michel Coindre, Karim Fizazi, (unknown)	17
19	Standards, Options et Recommandations (SOR) pour la surveillance et la prévention des infections nosocomiales en cancérologie 2000 ·Bulletin du Cancer ·(unknown), Raoul Herbrecht, M P Blanc-Vincent, (unknown), (unknown), Christine Fuhrmann, F. Crokaert, (unknown), Jean-Marcel Senet, Thierry Lesimple, (unknown), (unknown), Pierre Biron, M. Viot	5
20	Standards, Options and Recommendations (SOR)for the surveillance and the prevention of cross infections in oncology 2000 ·Bulletin du Cancer ·(unknown), Raoul Herbrecht, M P Blanc-Vincent, (unknown), (unknown), Christine Fuhrmann, F. Crokaert, (unknown), Jean-Marcel Senet, Thierry Lesimple, (unknown), (unknown), Pierre Biron, M. Viot	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact